Immunization of Cancer Patients with HER-2/neu-Derived Peptides Demonstrating High-Affinity Binding to Multiple Class II Alleles

Clinical Cancer Research

Volumn 9, Issue 15, 2003, Pages 5559-5565

  Salazar, Lupe G ^a,d   Fikes, John ^b   Southwood, Scott ^b   Ishioka, Glenn ^b   Knutson, Keith L ^a   Gooley, Theodore A ^c   Schiffman, Kathy ^a   Disis, Mary L ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Epimmune   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE DERIVATIVE; VACCINE;

ADULT; AGED; ALLELE; ANTIBODY RESPONSE; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BREAST CANCER; CANCER PATIENT; CELL SPECIFICITY; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPETITIVE INHIBITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EVALUATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; LUNG NON SMALL CELL CANCER; MOLECULAR INTERACTION; ONCOGENE NEU; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ADULT; AGED; ALLELES; BREAST NEOPLASMS; CANCER VACCINES; FEMALE; GENES, ERBB-2; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNITY, CELLULAR; MIDDLE AGED; PEPTIDE FRAGMENTS; T-LYMPHOCYTES;

EID: 0345060456     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Disis. M. L., Gooley, T. A., Rinn, K., Davis, D., Piepkorn, M., Cheever, M. A., Knutson, K. L., and Schiffman, K. Generation of T-cell immunity to the her-2/neu protein after active immunization with her-2/neu Peptide-based vaccines. J. Clin. Oncol., 20: 2624-2632, 2002.
2. Knutson, K. L., Schiffman, K., and Disis, M. L. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J. Clin. Investig., 107: 477-484, 2001.
3. Southwood, S., Sidney, J., Kondo, A., del Guercio, M. F., Appella, E., Hoffman, S., Kubo, R. T., Chesnut, R. W., Grey, H. M., and Sette, A. Several common HLA-DR types share largely overlapping peptide binding repertoires. J. Immunol., 160: 3363-3373, 1998.
4. Reece, J. C., Geysen, H. M., and Rodda, S. J. Mapping the major human T helper epitopes of tetanus toxin. The emerging picture. J. Immunol., 151: 6175-6184, 1993.
5. Disis, M. L., Grabstein, K. H., Sleath, P. R., and Cheever, M. A. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin. Cancer Res., 5: 1289-1297, 1999.
6. Disis, M. L., Knutson, K. L., Schiffman, K., Rinn. K., and McNeel, D. G. Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. Breast Cancer Res. Treat., 62: 245-252. 2000.
7. Disis, M. L., Calenoff, E., McLaughlin, G., Murphy, A. E., Chen, W., Groner, B., Jeschke, M., Lydon, N., McGlynn, E., and Livingston, R. B. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res., 54: 16-20, 1994.
8. Press, M. F., Cordon-Cardo, C., and Slamon, D. J. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene, 5: 953-962, 1990.
9. Kawashima, I., Hudson, S. J., Tsai, V., Southwood, S., Takesako, K., Appella, E., Sette, A., and Celis, E. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum. Immunol., 59: 1-14, 1998.
10. Sette, A., Vitiello, A., Reherman, B., Fowler, P., Nayersina, R., Kast, W. M., Melief, C. J., Oseroff, C., Yuan, L., and Ruppert, J. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J. Immunol., 153: 5586-5592, 1994.
11. Huarte, E., Sarobe, P., Lu, J., Casares, N., Lasarte, J. J., Dotor, J., Ruiz, M., Prieto, J., Celis, E., and Borras-Cuesta, F. Enhancing immunogenicity of a CTL epitope from carcinoembryonic antigen by selective amino acid replacements. Clin. Cancer Res., 8: 2336-2344, 2002.
12. Parkhurst, M. R., Salgaller, M. L., Southwood, S., Robbins, P. F., Sette, A., Rosenberg, S. A., and Kawakami, Y. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J. Immunol., 157: 2539-2548, 1996.
13. Borras-Cuesta, F., Golvano, J., Garcia-Granero, M., Sarobe, P., Riezu-Boj, J., Huarte, E., and Lasarte, J. Specific and general HLA-DR binding motifs: comparison of algorithms. Hum. Immunol., 61: 266-278, 2000.
14. Fairchild, P. J., and Wraith, D. C. Lowering the tone: mechanisms of immunodominance among epitopes with low affinity for MHC. Immunol. Today, 17: 80-85, 1996.
15. d-restricted peptides define the same immunodominant region of the measles virus fusion protein. Mol. Immunol., 32: 37-47, 1994.
16. Kedl, R. M., Rees, W. A., Hildeman, D. A., Schaefer, B., Mitchell, T., Kappler, J., and Marrack, P. T. cells compete for access to antigen-bearing antigen-presenting cells. J. Exp. Med., 192: 1105-1113, 2000.
17. Alexander, J., Oseroff, C., Dahlberg, C., Qin, M., Ishioka, G., Beebe, M., Fikes, J., Newman, M., Chesnut, R. W., Morton, P. A., Fok, K., Appella, E., and Sette, A. A. decaepitope polypeptide primes for multiple CD8+ IFN-γ and Th lymphocyte responses: evaluation of multiepitope polypeptides as a mode for vaccine delivery. J. Immunol., 168: 6189-6198, 2002.